Faslodex (fulvestrant), a new drug for metastatic breast cancer
You'll start hearing about Faslodex (fulvestrant), a new drug for metastatic breast cancer.
It's for postmenopausal women whose cancer progresses on tamoxifen or another antiestrogen.
In these women, Faslodex delays tumor progression at least as well as the aromatase inhibitor Arimidex (anastrozole).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote